Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBelluscura Regulatory News (BELL)

Share Price Information for Belluscura (BELL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.50
Bid: 7.00
Ask: 8.00
Change: 0.25 (3.45%)
Spread: 1.00 (14.286%)
Open: 7.25
High: 7.50
Low: 7.25
Prev. Close: 7.25
BELL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

The Pulse: Healthcare Innovation Breakfast

1 Nov 2021 07:00

RNS Number : 7860Q
Belluscura PLC
01 November 2021
 

Belluscura PLC

("Belluscura" or the "Company")

 

The Pulse: Healthcare Innovation Breakfast

 

CEO to present with London Stock Exchange Head of Primary Markets at event in Dallas, Texas

 

Bob Rauker to discuss accessing alternative sources of capital and his experience of listing a Company on the Alternative Investment Market (AIM) 

 

LONDON, U.K. AND PLANO, TX, U.S. (1 November 2021). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that CEO Robert "Bob" Rauker will be presenting alongside Chris Mayo, Head of Primary Markets (Americas), London Stock Exchange, at The Pulse Healthcare Innovation Breakfast event taking place in Dallas, Texas, USA, tomorrow.

 

The hybrid event, which is also supported by Department for International Trade (DIT), is designed to highlight how US based companies are taking advantage of lower cost execution and maintenance of a UK listing. The speakers will also discuss the high quality investor base for smaller companies and the ongoing access to capital in London which has proven attractive to emerging US growth companies. At the event, Bob Rauker will explain the benefits of Belluscura's London IPO and take Q&A with Rachel Carroll, President & Managing Partner of Edison Group, a global independent equity research and investor relations firm.

 

Health Wildcatters, an organisation which provides investment and key resources to support healthcare entrepreneurs, is hosting the in-person event on Tuesday 2 November at 07:30am - 09:00am CT. Those unable to be present are encouraged to attend a virtual meeting to be held via Zoom between the hours of 08:00am - 09:00am CT on the same day.

 

Interested parties can register for the event, below:

In Person: http://ow.ly/5cbi50Gnj8z

Virtual: http://ow.ly/QtXv50Gnj8x

A link to the Wildcatters website with the presentation information: https://www.healthwildcatters.com/

 

The event is being recorded and will be available on the Health WildCatters Youtube channel: https://www.youtube.com/c/HealthWildcattersDallas/videos

 

Chris Mayo will briefly set the scene as to why many smaller US emerging growth companies are looking to London Stock Exchange after an introduction by Hubert Zajicek, MD, MBA and Geraldine SCHOTT, PhD of the Department for International Trade (DIT).

 

About Reach announcements

 

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

 

For further information please contact:

 

Belluscura plc

www.belluscura.com

Robert Rauker, Chief Executive Officer

via Walbrook PR

Anthony Dyer, Chief Financial Officer

 

 

 

SPARK Advisory Partners Limited (NOMAD)

Tel: +44 (0)20 3368 3550

Neil Baldwin

 

 

 

Dowgate Capital Limited (Broker)

Tel: +44 (0)20 3903 7715

James Serjeant / Nicholas Chambers

 

 

 

Walbrook PR Ltd (Media & Investor Relations)

Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com

Paul McManus / Sam Allen

Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

 

 

About Belluscura plc (www.belluscura.com)

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABUBDGDBDDGBC
Date   Source Headline
13th Dec 20227:00 amRNSFirst international distribution agreement
14th Nov 20224:40 pmRNSSecond Price Monitoring Extn
14th Nov 20224:35 pmRNSPrice Monitoring Extension
14th Nov 20222:06 pmRNSSecond Price Monitoring Extn
14th Nov 20222:00 pmRNSPrice Monitoring Extension
14th Nov 202211:05 amRNSSecond Price Monitoring Extn
14th Nov 202211:00 amRNSPrice Monitoring Extension
10th Nov 20227:00 amRNSBelluscura receives certification to ISO standard
31st Oct 20225:46 pmRNSHolding(s) in Company
31st Oct 20225:41 pmRNSDirector/PDMR Shareholding
31st Oct 20225:38 pmRNSDirector/PDMR Shareholding
24th Oct 20227:00 amRNSBelluscura wins two HME Business Awards
23rd Sep 202211:45 amRNSHolding(s) in Company
20th Sep 20227:01 amRNSHalf-year Report
20th Sep 20227:00 amRNSBelluscura signs agreement with US distributor
6th Sep 20227:00 amRNSNotice of Results
18th Aug 20221:25 pmRNSDirector/PDMR Shareholding
10th Aug 20227:00 amRNSDirector/PDMR Shareholding
2nd Aug 20222:26 pmRNSAgreement with VGM, largest MSO in US-replacement
2nd Aug 202212:53 pmRNSAgreement with VGM, largest DSO in US-replacement
2nd Aug 20227:00 amRNSSupply Agreement with VGA, largest MSO in the US
15th Jul 20227:00 amRNSWarrant Exercise
14th Jul 20227:00 amRNSExercise of Warrants
30th Jun 20227:00 amRNSDirect to Consumer Sales and Distribution Plan
27th Jun 20227:00 amRNSLaunch of Next Gen X-PLOR Oxygen Concentrator
25th May 20221:19 pmRNSTR-1: Notification of major holdings
24th May 20225:27 pmRNSTR-1: Notification of major holdings
19th May 20227:00 amRNSBelluscura Expands its Patent Portfolio
17th May 202212:00 pmRNSApplications Announcement
13th May 202211:00 amRNSResult of Placing
12th May 20225:01 pmRNSProposed placing to raise £5.0m
25th Apr 20221:00 pmRNSResult of AGM
21st Apr 20227:00 amRNSSenior Management Appointment
7th Apr 20227:00 amRNSDAPA Contract
5th Apr 20226:31 pmRNSHolding(s) in Company
5th Apr 20227:00 amRNSSenior Management Appointment
1st Apr 20227:00 amRNSNotice of AGM and Annual Report 2021
30th Mar 20227:00 amRNSManufacturing Agreement
22nd Feb 20227:00 amRNSFinal Results
27th Jan 202211:06 amRNSSecond Price Monitoring Extn
27th Jan 202211:00 amRNSPrice Monitoring Extension
24th Jan 20227:00 amRNSTrading Update and Notice of Preliminary Results
20th Jan 20222:32 pmRNSExercise of Warrants and Total Voting Rights
13th Jan 202211:05 amRNSSecond Price Monitoring Extn
13th Jan 202211:00 amRNSPrice Monitoring Extension
7th Dec 20217:00 amRNSExercise of Warrants and Total Voting Rights
29th Nov 20217:01 amRNSReimbursement approvals
29th Nov 20217:00 amRNSExercise of Warrants and Total Voting Rights
4th Nov 20217:00 amRNSTrading update
1st Nov 20217:00 amRNSThe Pulse: Healthcare Innovation Breakfast

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.